Continuing Pharmacy Education / CE Master List / Henry A. Palmer CE Finale LIVE Event Friday, Dec 19, 2025
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Henry A. Palmer CE Finale LIVE Event Friday, Dec 19, 2025

Photograph of Henry A. Palmer

The School of Pharmacy Henry A. Palmer CE Finale, named for beloved professor and mentor, Dr. Henry A. Palmer, is a continuing education program offered at the end of each calendar year. Held during December, the program helps pharmacists fulfill their last minute CE requirements. The program is typically not a single theme, but an ala carte program offering a variety of presentations covering contemporary issues in pharmacy practice/therapeutics. Pharmacists may enroll in one or more [up to 8] hours of continuing education.

The University of Connecticut

School of Pharmacy

Presents the

Henry A. Palmer C.E. FINALE 2025

Doppelgangers, Imposters, and New Kids on the Block

A LIVE (both virtual and in-person) application and knowledge-based continuing education activity for practicing pharmacists in all settings

 

Friday, December 19, 2025

7:30 AM – 5:00 PM Eastern Time
Sheraton Hartford South, Rocky Hill, CT

For a full course description see the Henry A. Palmer CE Finale Brochure 2025

REGISTRATION

Handouts for CE Finale will be available the first week of December

 

 

CE FINALE 2025 SCHEDULE/TOPICS/LEARNING OBJECTIVES

7:30-8:00 a.m. – Registration and Check-In/Sign-In

8:00-8:05 a.m. – Opening Remarks- Phil Hritcko, Dean and Clinical Professor, University of Connecticut School of Pharmacy

8:05-8:10 a.m. – Operational Instructions– Jeannette Y. Wick, RPh, MBA, Director of the Office of   Professional Pharmacy Development, University of Connecticut School of Pharmacy, Storrs, CT

 

8:10 – 9:10 a.m. – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain

Jeannette Y. Wick, RPh, MBA, Director of the Office of Professional Pharmacy Development, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to
  1. Define the terms “counterfeit” and “spurious” drugs
  2. Discuss the prevalence of counterfeiting globally and in the United States
  3. List factors that contribute to drug counterfeiting
  4. Discuss the Drug Supply Chain Security Act (DSCSA) and its implications for the drug supply distribution chain’s integrity
  5. Identify steps that reduce the risk of suspect product being delivered to the pharmacy and to patients

0009-0000-25-062-L03-P (0.1 CEU or 1 contact hour) (Application-based)

 

9:15 – 10:15 a.m. – Step by Step: Tackling Imposter Syndrome in Every Transition

Jennifer Luciano, PharmD, Director of Office of Experiential Education, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to
1.       Recognize the signs and symptoms of imposter syndrome as they commonly present in pharmacy practice and education, including during career transitions such as rotations, residency, and new professional roles

2.       Examine the personal, academic, and systemic factors that contribute to imposter syndrome among pharmacists and pharmacy students, with emphasis on high-performance expectations and professional identity formation

3.       Identify practical, evidence-based strategies to manage and overcome imposter syndrome, fostering resilience, confidence, and professional growth within pharmacy practice and education

0009-0000-25-063-L99-P  (0.1 CEU or 1 contact hour) (Application-based)

 

10:20-11:20 a.m. – NKOTB: 2025 Updates on Management of Hypertension in Adults

William L. Baker, PharmD, FCCP, FACC, FHFSA, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to
  1. Review the 2025 hypertension guidelines
  2. Compare the updated recommendations to the prior guidelines
  3. Review the evidence supporting the guideline changes

0009-0000-25-064-L01-P (0.1 CEU or 1 contact hour) (Application-based)

 

11:25-12:25 p.m.  – NKOTB: New and Emerging Roles for GLP-1-Based Medications

Devra Dang, PharmD, CDCES, FNAP, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT  

At the conclusion of this presentation, pharmacists will be able to
1.       List recent FDA-approved indications for GLP-1-based medications

2.       Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type

3.       Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications

0009-0000-25-065-L01-P (0.1 CEU or 1 contact hour) (Knowledge-based)

 

12:25-12:45 p.m. – BREAK. Light snacks will be served.

 

12:45-1:45 p.m. – PATIENT SAFETY: Biosimilar Doppelgangers

Michael White, PharmD, FCP, FCCP, FASHP, Distinguished Professor and Chair, Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to
1.       Compare and contrast a small molecule drug from a biological drug

2.       Compare and contrast how a reference biologic drug compares with its biosimilar

3.       Describe where a pharmacist would identify a biosimilar product and the legal implications of a biosimilar achieving interchangeable status with a reference product

4.       Describe the nocebo effect and how to prevent it from occurring

5.       Apply the knowledge from the objectives above to specific patient care scenarios in the self-assessment questions

0009-0000-25-066-L05-P (0.1 CEU or 1 contact hour) (Application-based)

 

1:50-2:50 p.m.  – Hormone Therapy’s Twin Faces: Sorting Science from Misconception

Kelsey Giara, PharmD, Freelance Medical Writer, Pelham, NH

At the conclusion of this presentation, pharmacists will be able to
  1. Discuss the clinical evidence on safety, efficacy, and patient outcomes for hormone replacement therapy (HRT), highlighting areas of misconception or confusion
  2. Compare HRT options and biosimilars, including mechanisms of action, formulations, and regulatory pathways
  3. Apply guidelines and evidence-based recommendations to individualize patient counseling and therapeutic decision-making when managing HRT

0009-0000-25-067-L01-P  (0.1 CEU or 1 contact hour (Application-based)

 

2:55-3:55 p.m.  – Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block

Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to
  1. Describe the unique mechanisms of action of xanomeline-trospium in the management of schizophrenia and dextromethorphan-containing medications in the management of major depressive disorder
  2. Distinguish between adverse effect profiles of new psychiatric medications compared to traditional antipsychotics and antidepressants
  3. Identify appropriate candidates for new psychiatric medications based on knowledge of efficacy, safety, and patient-specific factors

0009-0000-25-068-L01-P  (0.1 CEU or 1 contact hour) (Application-based)

 

4:00-5:00 p.m. – IMMUNIZATION: Immunizations: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025

Jeff Aeschlimann, PharmD, University of Connecticut, Storrs, CT

At the conclusion of this presentation, pharmacists will be able to
  1. Describe at least one important change (or proposed change) in childhood and adult vaccination recommendations put forth by the CDC and/or ACIP
  2. Given a patient who asks about receiving respiratory virus or bacteria vaccinations (e.g., Influenza, COVID-19, respiratory syncytial virus (RSV), pneumococcal), outline important differences between multiple products when they exist
  3.  Identify evidence-based pharmacotherapeutic treatments for common vaccine-preventable illnesses

0009-0000-25-069-L06-P (0.1 CEU or 1 contact hour) (Application-based)

 

 

CE FINALE ENCORE WEBINARS AVAILABLE

If you find you cannot make it to our LIVE EVENT on Friday, December 19th, you can participate in our ENCORE LIVE WEBINARS that will be streamed on the following dates:

  • Monday, December 22, 12:00 (Noon) – 1:00 pm – NKOTB: New and Emerging Roles for GLP-1-Based Medications
  • Monday, December 22, 7:00 pm-8:00 pm – Hormone Therapy’s Twin Faces: Sorting Science from Misconception
  • Monday, December 22, 8:10 – 9:10 pm – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain
  • Tuesday, December 23, 12:00 pm-1:00 pm – PATIENT SAFETY: Biosimilar Doppelgangers
  • Tuesday, December 23, 7 pm – 8 pm – IMMUNIZATION: Immunizations: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025
  • Monday, December 29, 12:00 (Noon) – 1:00 pm – Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block
  • Monday, December 29, 7 pm – 8 pm – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain
  • Tuesday, December 30, 12:00 (Noon) – 1:00 pm – NKOTB: 2025 Updates on Management of Hypertension in Adults
  • Tuesday, December 30, 7 pm – 8 pm – Step by Step: Tackling Imposter Syndrome in Every Transition

 

Registration Brochure:

 

 

A continuous class schedule format will be used.  This format does not include breaks but does include a 20-minute lunch period.

 

Refunds and Cancellations: The registration fee, less a $75 processing fee, is refundable for those who cancel their registration three (3) days prior to the program (by December 16) After that time, no refund is available.

 

Location: The Henry A. Palmer C.E. Finale will be held both virtually and in-person. You must sign in to the Webex link at the designated time using the link in your confirmation email if you decide to participate virtually.

ACPE Logo

Continuing Education Units

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 8 contact hours (0.80 CEU) one of which is a law credit, one is an Immunization Credit, and one is a Patient Safety Credit.

 

Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (before February 1, 2026).  Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with Heather.Kleven@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to ensure that your credits have been properly uploaded.  Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

 

Activity Support:  There is no funding for this program.

 

Registration Form – ONLINE PLEASE, our paper check processing system is quite slow.

Henry A. Palmer C.E. Finale 2025 – December 19, 2025, and CE Finale Encore Webinars December 22-30, 2025.  Registration AFTER December 10, will incur a $25 late fee.